Spero Therapeutics (SPRO) announced a $105 million non-recourse, non-dilutive royalty financing transaction with affiliates of Healthcare Royalty (HCRx), majority owned by KKR. The company said proceeds will primarily be used to support its operations/financing needs (details not fully provided in the excerpt). Overall, the structure is credit-like and avoids share dilution, which is modestly positive for funding risk.
Spero Therapeutics (SPRO) announced a $105 million non-recourse, non-dilutive royalty financing transaction with affiliates of Healthcare Royalty (HCRx), majority owned by KKR. The company said proceeds will primarily be used to support its operations/financing needs (details not fully provided in the excerpt). Overall, the structure is credit-like and avoids share dilution, which is modestly positive for funding risk.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
